Welcome to Patchor

New Generation for HA-Viscosupplementation

Patchor Ltd., an Israeli company, is operating from 2015. Patchor is engaged in development of an innovative HA-based viscosupplementation products for the orthopedic market, particularly Osteoarthritis (OA) of the knee which is a clinical challenge.

Osteoarthritis, affecting millions of people all over the world, arises from defects in cartilage that cause deterioration of its protective role on the ends of bones.

The OA market is continuously growing with aging and with epidemic proportions of metabolic diseases, such as obesity.

Worldwide-market for knee-OA is currently reaching $3-billion, and $1-billion in the USA.

Technology

Patchor patented technology combines components, that have already been proven effective in patients, into one injectable HA-based viscosupplementation 3rd generation product.

Advantages

Medical advantages

• Prolongs HA residence time similar to cross-linked HA

• Combines clinically proven beneficial effects of each of its components:

  • Cushioning

  • Regeneration

  • Anti-inflammatory

  • Anti-fibrotic

Commercial advantages

• Similar but innovative and better product in a well-established HA market

• Minimally invasive injectable gel-forming liquid  

• Strong differentiation potential in market

• Technological platform

• High technological barrier

• Biodegradation products support joint health